The partnership has enabled Viralgen to scale up and complete a GMP trial material batch of Trogenix's therapy.

The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a market size of USD 24.6 Billion by 2032 growing at a CAGR of 18.5% from ...

GEN talked with several contract development and manufacturing organizations (CDMOs) and/or contract research organizations (CROs) about new ways they are addressing AAV manufacturing challenges.

“Unfortunately, this means we’ve made the difficult decision to cease vector manufacturing in Libertyville, a site that has operated at the highest level for BMS Cell Therapy,” she adde ...

AnelloBricks is a promising in vitro approach to producing a new class of functional viral vectors, offering dramatic advantages in manufacturing scalability and cost compared to ...

Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, ...

Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieum Biotechnologies, Inc. (Optieum), a preclinical stage company dedicated to the discovery and ...